Tandem autologous-reduced intensity allogeneic stem cell transplantation in high-risk relapsed Hodgkin lymphoma: a retrospective study of the Lymphoma Working Party

Tandem autologous-reduced intensity allogeneic stem cell transplantation in high-risk relapsed Hodgkin lymphoma: a retrospective study of the Lymphoma Working Party—EBMT

Published:2020-10-12 Issue:3 Volume:56 Page:655-663
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Bento Leyre^ORCID,Boumendil Ariane,Finel Hervé,Khvedelidze Irma,Blaise Didier^ORCID,Fegueux Nathalie,Castagna Luca,Forcade Edouard,Chevallier Patrice,Mordini Nicola,Brice Pauline,Deconinck Eric,Gramatzki Martin,Corradini Paolo^ORCID,Hunault Mathilde^ORCID,Musso Maurizio,Tsoulkani Anna,Caballero Dolores,Nati Sandro,Montoto Silvia,Sureda Anna,

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

https://www.nature.com/articles/s41409-020-01075-y.pdf

Reference28 articles.

1. Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet. 2002;359:2065–71.

2. Younes A, Sureda A, Ben-Yehuda D, Zinzani PL, Ong T-C, Prince HM, et al. Panobinostat in patients with relapsed/refractory Hodgkin’s lymphoma after autologous stem-cell transplantation: results of a phase II study. J Clin Oncol. 2012;30:2197–203.

3. Gibb A, Jones C, Bloor A, Kulkarni S, Illidge T, Linton K, et al. Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK center. Haematologica. 2013;98:611–4.

4. Corazzelli G, Angrilli F, D’Arco A, Ferrara F, Musto P, Guarini A, et al. Efficacy and safety of bendamustine for the treatment of patients with recurring Hodgkin lymphoma. Br J Haematol. 2013;160:207–15.

5. Anastasia A, Carlo-Stella C, Corradini P, Salvi F, Rusconi C, Pulsoni A, et al. Bendamustine for Hodgkin lymphoma patients failing autologous or autologous and allogeneic stem cell transplantation: a retrospective study of the Fondazione Italiana Linfomi. Br J Haematol. 2014;166:140–2.

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Outcome of High-Dose Chemotherapy Followed by Autologous Stem Cell Transplantation in Relapsed/Refractory Hodgkin Lymphoma after Different Numbers of Salvage Regimens;Cells;2024-01-09

2. Sequential autologous and allogeneic stem cell transplantation for treatment of primary plasma cell leukemia: A case report;Molecular and Clinical Oncology;2023-08-02

3. Single or tandem autologous stem cell transplantation for treating Chinese patients with refractory/relapsed classical Hodgkin lymphoma;Cancer Medicine;2023-04-20

4. Advances in the treatment of Hodgkin lymphoma: Current and future approaches;Frontiers in Oncology;2023-03-03

5. Filling the Gap: The Immune Therapeutic Armamentarium for Relapsed/Refractory Hodgkin Lymphoma;Journal of Clinical Medicine;2022-11-06